NeuroMab™ Anti-EGFR BBB Shuttle Antibody,Clone NR1823P

Figure 1 shows the competitive ELISA using HuMabs 6B3, 5F12, 2F8.

Figure 2 shows inhibition of EGF-biotin binding to EGFR by anti-EGFR HuMabs and murine MAbs (ELISA format).

Figure 3 is a graph showing that anti-EGFR HuMabs and murine MAbs inhibit EGF-biotin binding to EGFR on A431 cells.

Figure 4 is a graph showing the titration of anti-EGFR HuMabs on A431 cells.

Figure 5 shows growth inhibition of EGFR expressing tumor cell lines by anti-EGFR human antibodies. The tumor cell line A431 expressing EGFR was mixed with various concentrations of HuMab 2F8 (square), 5C5 (triangle), 6E9 (cross), 2A2 (diamond) antibody negative control anti-CTLA4 (open circle), antibody positive control 225 (closed circle ) or medium only (control) for seven (7) days.

Figure 6 shows growth inhibition of EGFR expressing tumor cell lines by anti-EGFR human antibodies. The tumor cell line HN5 expressing EGFR was mixed with various concentrations of HuMab 2F8 (square), 5C5 (triangle), 6E9 (cross), 2A2 (diamond) antibody negative control anti-CTLA4 (open circle), antibody positive control 225 (closed circle ) or medium only (control) for seven (7) days.

Figure 7 is a graph showing antibody-dependent cytotoxicity mediated by human PMN.

PMNs were isolated as described. 51 Chromium-labeled A431 cells were seeded in 96-well flat bottom plates. PMNs were added at an effector:target ratio of 100:1 and antibodies were added at various concentrations. After overnight incubation, the release of 51Cr was measured.